Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Compare the acute effects and tolerability of Dihydroergotamine Mesylate (DHE) delivered by
Oral Inhalation (MAP0004) versus by intravenous (IV) infusion in healthy adult volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Allergan
Collaborator:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan